

CRO Communiqué
Keeping you informed about CRO progress
April 2012

Top Enrolling Physicians for March 2012

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Yaqoob Ali	1	0	1	1
Dr. Brian Biggers	2	0	2	2
Dr. Joseph Bond	1	1.3	0	1.3
Dr. Bonebrake	4	2.3	1.5	3.8
Dr. Cunningham	1	1	0.5	1.5
Dr. Robert Ellis	1	1	0	1
Dr. Gary Hoos	2	1	1	2
Dr. Manjula Raju	2	0	2	2
Dr. Lavanya Tiriveedhi	4	2.5	2	4.5
TOTALS	18	9.1	10	19.1

WOW! March was another great month for accruals. We have surpassed our NCI assigned cancer control credits of 60 for this grant year as we have now earned 72.4 control credits. We currently have 95.8 treatment credits and need to be at 100 to meet our target treatment credits this grant year. With two months remaining in our grant year it is very possible for us to meet our NCI assigned treatment credits as well. Thanks to each of you for your support.

CRO Web based monthly Educational Conference

CRO's monthly educational web conference to discuss new studies and other things happening at CRO will begin in May. We will be hosting two calls per month initially to meet the preferences of the medical oncologists at Cox and Mercy. Monday, May 7th at 12 noon will be the first conference. Tuesday, May 8th at 5pm will be the second call. Going forward our conference calls will be scheduled on the Monday before the first Tuesday of the month at 12noon and the second Tuesday of the month at 5pm. The conferences will consist of Dr. Carolla and possibly other physicians presenting new studies. Our target audience is our investigators, nurse practitioners and research staff. Our affiliate investigators and staff are highly encouraged to join in. CME's will be given for attendance. We will be using the WebEx tool which is highly interactive with logon capabilities from home, iPhones, iPads, Blackberries and so on as well as video capabilities with a web-cam. For the first several months we will be setting up the conference rooms at Cancer Hematology Center and Oncology Hematology Associates for our investigators and interested staff to join in as a group. If this is helpful and well attended we will make further plans to do this on a permanent basis. Others will receive an email with directions for phoning in and logging onto the conference. Please email Debbie Cane at Debbie.Cane@CoxHealth.com or myself at Marilyn.Bauer@CoxHealth.com with your contact information if you wish to receive notice of our monthly conferences and are not an investigator, nurse practitioner or member of our staff in Springfield. We see this as an opportunity to improve communications with our investigators and research staff.

Study Profile

SWOG S0927 "A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III" is this month's study to profile. This trial is for women with histologically confirmed primary invasive adenocarcinoma of the breast (Stage I, II, or III) with no evidence of metastatic disease. They must have undergone a modified radical mastectomy or breast sparing surgery and have recovered from the surgery. Patients must be post-menopausal, be positive for either estrogen receptor and/or progesterone receptor, and currently taking a third-generation aromatase inhibitor – anastrozole (Arimidex), letrozole (Femara), or exemestane (Aromasin) for at least the previous 90 days prior to registration with plans to continue for at least an additional 180 days after registration. The study is blinded and patients are randomized to receive the Omega 3-fatty acid or a placebo.

Steering Committee Meeting

Our next CRO Steering Committee will be Thursday, May 3rd at TOUCH Restaurant. Alain Mita MD, Co-Director, Experimental Therapeutics Program at Cedar-Sinai Medical Center will speak on "The

Molecular Basis of Lung Cancer: Expand your Understanding on Lung Cancer Biology”. Educational objectives for this program include:

- Refresh key concepts in cell-signaling pathways related to cancer biology
- Update knowledge on targeted therapeutic approaches and their mechanisms of action in an unbranded environment
- Share experiences and network with fellow oncologists through scientific discussions in a collegial atmosphere

Please RSVP to Debbie.Cane@CoxHealth.com or 417-269-4520 by April 30, 2012.

New Studies Approved in March 2012

Opened at Cox and St. John's

CTSU CALGB 80803 Randomized Phase II Trial Of Pet Scan-Directed Combined Modality Therapy In Esophageal Cancer

GOG-0274 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL

SWOG 0V.21 A Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy

Opened at Cox only

CTSU NCCTG N1048 A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

GOG 0207 A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 3 (CIN 3) (IND#69,656)

Studies Permanently Closed to Enrollment at Cox & St. John's in March 2012

SWOG S0500 A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment

SWOG S0802 A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)